潘柯博士作为亚虹医药的创始人、董事长、首席执行官，不忘初心，始终坚持带领企业走创新之路，聚焦泌尿生殖系统肿瘤赛道，公司秉承 "改善人类健康，让生命更有尊严"的使命，期望为患者提供更多创新的治疗选择，积极推动中国医药健康产业的高质量发展。Shanghai9 November 2023 /PRNewswire/ -- On November 8, the “2nd Taishan Pharmaceutical Forum” hosted by the Pharmaceutical Chamber of Commerce of the All-China Federation of Industry and Commerce and the Taishan Pharmaceutical Forum Organizing Committee was held in Jinan, Shandong Province. Dr. Pan Ke, founder, chairman and CEO of Yahong Pharmaceutical, won the “2022-2023 Top 100 People Promoting High-Quality Development of the Medical and Health Industry” award.
With the theme of the pharmaceutical industry “Full Industry, Big Platform, Deep Integration, and Co-development”, the forum focused on the development of the medical and health industry and conducted in-depth discussions. More than 1,000 people from the national healthcare industry attended the conference to discuss industry development and witness the announcement of the “Top 100 People Promoting the High-Quality Development of the Medical and Health Industry” award.
In order to help the State Council implement the “Action Plan for the High Quality Development of the Pharmaceutical Industry (2023-2025)” and the “Action Plan for the High Quality Development of the Medical Equipment Industry (2023-2025)”, the “Top 100 People Promoting the High-Quality Development of the Medical and Health Industry 2022-2023” award was selected by the Pharmaceutical Industry Chamber of Commerce of the China Federation of Industry and Commerce and the Taishan Pharmaceutical Forum Organizing Committee, with the aim of commending the advanced, setting a benchmark, and playing a leading role model.
As the founder, chairman and CEO of Yahong Pharmaceutical, Dr. Pan Ke never forgets his original intention. He always adheres to the path of innovation and focuses on the urogenital cancer circuit. The company adheres to the mission of “improving human health and making life more dignified”, hopes to provide patients with more innovative treatment options, and actively promotes the high-quality development of China's medical and health industry.
About Yahong Pharmaceutical
Established in March 2010, Yahong Pharmaceutical (stock code: 688176.SH) is a global innovative pharmaceutical company focusing on urogenital tumors and other major diseases. Adhering to the corporate mission of “improving human health and making life more dignified”, Yahong Pharmaceutical aims to become a leading international pharmaceutical company integrating R&D, production and commercialization in the field of treatment, providing the best integrated diagnosis and treatment solutions for patients in China and around the world.
The company insists on innovative technology and products as the core driving force. By building its own R&D platform and core technology, the company thoroughly explores the mechanism of action of drugs and efficiently screens and evaluates drug candidates. Through a complete internal R&D system and global drug development expertise, Yahong Pharmaceutical is committed to launching first-in-class (first-in-class) drugs and other innovative drugs with huge unmet treatment needs in therapeutic areas.
At the same time, through independent research and development and strategic cooperation, Yahong Pharmaceutical has carried out in-depth product pipeline layout around urogenital diseases, paid great attention to cutting-edge technology and treatment trends in this field, discovered and explored unmet clinical needs, carried out forward-looking product planning and life cycle management, and created an advantageous product portfolio covering disease diagnosis to treatment, thus benefiting more patients in China and around the world.
